KalVista Pharmaceuticals Inc. has announced the acceptance of six abstracts for ePoster presentation at the upcoming 20th German Allergy Congress, scheduled to take place in Düsseldorf, Germany, from October 2-4, 2025. The presentations will cover new data on EKTERLY® (sebetralstat), including its use for the on-demand treatment of hereditary angioedema $(HAE)$ attacks, its impact on anxiety associated with HAE, and its effectiveness in patients already receiving berotralstat. The results from these studies will be presented at the congress, with further details and links to all presentations available on the KalVista website under Publications.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalvista Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250926150381) on September 26, 2025, and is solely responsible for the information contained therein.